BACKGROUND: Maintenance therapy with interferon-alpha after high-dose treatment with stem cell support in multiple myeloma has been intensively debated. In this study, we evaluated the response to treatment with interferon-alpha in relation to genetic variation in genes related to inflammation. DESIGN AND METHODS: In a retrospective study of 296 patients with multiple myeloma undergoing high-dose therapy between 1994 and 2004, 146 patients were treated with interferon-alpha as maintenance therapy. We tested the polymorphisms IL1B T-31C, IL6 G-174C, NFKB1-94ins/delATTG, CD3EAP G-21A and PPP1R13L IVS1 A4364G for associations with time to treatment failure and overall survival with and without interferon-alpha treatment. RESULTS: The wild type ins-allele of polymorphism NFKB1-94 ins/delATTG was, by multivariate Cox analysis, associated with longer time to treatment failure (p=0.01) and overall survival (p=0.0084) when tested between treatment arms and in the subgroup of patients treated with interferon-alpha the wild type ins-allele was associated with longer overall survival (p=0.002). In the absence of interferon-alpha treatment, there was no association between the polymorphisms and treatment outcome, except for patients homozygous for the wild type G allele of IL6 G-174C who survived longer (p= 0.0074) than variant allele carriers. There was no association between the polymorphisms IL1B T-31C, CD3EAP G-21A and PPP1R13L IVS1 A4364G and treatment outcome for interferon-alpha. CONCLUSIONS: Patients who are homozygous carriers of the wild type ins-allele of the NFKB1 -94ins/delATTG polymorphism may benefit from treatment with interferon-alpha, in contrast to patients carrying the variant allele. This result may indicate that the effect of interferon-alpha treatment is dependent on the availability of nuclear factor-kappaB and the polymorphism in NFKB1 may, therefore, be a good prognostic marker for multiple myeloma patients on maintenance treatment with interferon-alpha after high-dose therapy. A prospective study of interferon-alpha treatment in relation to NFKB1 -94ins/delATTG is highly warranted.
BACKGROUND: Maintenance therapy with interferon-alpha after high-dose treatment with stem cell support in multiple myeloma has been intensively debated. In this study, we evaluated the response to treatment with interferon-alpha in relation to genetic variation in genes related to inflammation. DESIGN AND METHODS: In a retrospective study of 296 patients with multiple myeloma undergoing high-dose therapy between 1994 and 2004, 146 patients were treated with interferon-alpha as maintenance therapy. We tested the polymorphisms IL1BT-31C, IL6 G-174C, NFKB1-94ins/delATTG, CD3EAP G-21A and PPP1R13L IVS1 A4364G for associations with time to treatment failure and overall survival with and without interferon-alpha treatment. RESULTS: The wild type ins-allele of polymorphism NFKB1-94 ins/delATTG was, by multivariate Cox analysis, associated with longer time to treatment failure (p=0.01) and overall survival (p=0.0084) when tested between treatment arms and in the subgroup of patients treated with interferon-alpha the wild type ins-allele was associated with longer overall survival (p=0.002). In the absence of interferon-alpha treatment, there was no association between the polymorphisms and treatment outcome, except for patients homozygous for the wild type G allele of IL6 G-174C who survived longer (p= 0.0074) than variant allele carriers. There was no association between the polymorphisms IL1BT-31C, CD3EAP G-21A and PPP1R13L IVS1 A4364G and treatment outcome for interferon-alpha. CONCLUSIONS:Patients who are homozygous carriers of the wild type ins-allele of the NFKB1-94ins/delATTG polymorphism may benefit from treatment with interferon-alpha, in contrast to patients carrying the variant allele. This result may indicate that the effect of interferon-alpha treatment is dependent on the availability of nuclear factor-kappaB and the polymorphism in NFKB1 may, therefore, be a good prognostic marker for multiple myelomapatients on maintenance treatment with interferon-alpha after high-dose therapy. A prospective study of interferon-alpha treatment in relation to NFKB1-94ins/delATTG is highly warranted.
Authors: A J Vangsted; T W Klausen; W Ruminski; P Gimsing; N F Andersen; A O Gang; N Abildgaard; L M Knudsen; J L Nielsen; H Gregersen; U Vogel Journal: Bone Marrow Transplant Date: 2008-11-10 Impact factor: 5.483
Authors: S Lenhoff; M Hjorth; E Holmberg; I Turesson; J Westin; J L Nielsen; F Wislöff; L Brinch; K Carlson; M Carlsson; I M Dahl; P Gimsing; E Hippe; H E Johnsen; H Johnsen; J Lamvik; E Löfvenberg; I Nesthus; S Rödjer Journal: Blood Date: 2000-01-01 Impact factor: 22.113
Authors: D Cunningham; R Powles; J Malpas; N Raje; S Milan; C Viner; A Montes; T Hickish; M Nicolson; P Johnson; J Treleaven; J Raymond; M Gore Journal: Br J Haematol Date: 1998-07 Impact factor: 6.998
Authors: Ulla Vogel; Imke Laros; Nicklas R Jacobsen; Birthe L Thomsen; Helle Bak; Anja Olsen; Zuzanna Bukowy; Håkan Wallin; Kim Overvad; Anne Tjønneland; Bjørn A Nexø; Ole Raaschou-Nielsen Journal: Mutat Res Date: 2004-02-26 Impact factor: 2.433
Authors: Amir S Karban; Toshihiko Okazaki; Carolien I M Panhuysen; Thomas Gallegos; James J Potter; Joan E Bailey-Wilson; Mark S Silverberg; Richard H Duerr; Judy H Cho; Peter K Gregersen; Yuqiong Wu; Jean-Paul Achkar; Themistocles Dassopoulos; Esteban Mezey; Theodore M Bayless; Franklin J Nouvet; Steven R Brant Journal: Hum Mol Genet Date: 2003-11-12 Impact factor: 6.150
Authors: Annette J Vangsted; Karen Søeby; Tobias W Klausen; Niels Abildgaard; Niels F Andersen; Peter Gimsing; Henrik Gregersen; Ulla Vogel; Thomas Werge; Henrik B Rasmussen Journal: BMC Cancer Date: 2010-08-04 Impact factor: 4.430
Authors: Jakob Gerhard Stegger; Erik Berg Schmidt; Anne Tjønneland; Tine Iskov Kopp; Thorkild I A Sørensen; Ulla Vogel; Kim Overvad Journal: PLoS One Date: 2012-06-29 Impact factor: 3.240
Authors: Cecília Durães; Carla S Moreira; Inês Alvelos; Adélia Mendes; Liliana R Santos; José Carlos Machado; Miguel Melo; César Esteves; Celestino Neves; Manuel Sobrinho-Simões; Paula Soares Journal: PLoS One Date: 2014-08-15 Impact factor: 3.240